European Union - English - EMA (European Medicines Agency)

acino pharma gmbh  - clopidogrel - peripheral vascular diseases - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome:- non st segment elevation acute coronary syndrome (unstable angina or non q wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.

European Union - English - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel hydrochloride - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotic agents - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease., - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy., , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke., , for further information please refer to section 5.1. , , ,

European Union - English - EMA (European Medicines Agency)

sloan pharma s.a.r.l - botulinum toxin type b - torticollis - muscle relaxants - neurobloc is indicated for the treatment of cervical dystonia (torticollis).see section 5.1 for data on efficacy in patients responsive / resistant to botulinum toxin type a.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - thiopental sodium, quantity: 0.5 g - injection, powder for - excipient ingredients: - indications as at 08 dec 1993 : pentothal may be used : 1. as the sole anaesthetic agent for brief surgical procedures; 2. for the induction of anaesthesia prior to the administration of other anaesthetic agents; 3. for the short-term control of condvulsive states; 4. to supplement regional anaesthesia or low potency agents such as nitrous oxide.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - procarbazine hydrochloride, quantity: 58.3 mg (equivalent: procarbazine, qty 50 mg) - capsule, hard - excipient ingredients: gelatin; iron oxide yellow; magnesium stearate; titanium dioxide; purified talc; mannitol; maize starch - indications as at 23 august 1991: treatment of hodgkin's disease (multiple lymphadenoma); treatment of other malignant lymphomas including lymphosarcoma, reticulosarcoma, brill-symmers disease. natulan is dissimilar to other cytostatic agents and may be effective in cases resistant to other drugs and x-rays.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - primidone, quantity: 250 mg - tablet, uncoated - excipient ingredients: carmellose calcium; povidone; gelatin; magnesium stearate; stearic acid - management of grand mal and psychomotor (temporal lobe) epilepsy. it is also of value in the management of focal or jacksonian seizures, myoclonic jerks and akinetic attacks.

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - foscarnet sodium hexahydrate 24 mg/ml - solution for infusion - 24 mg/ml - active: foscarnet sodium hexahydrate 24 mg/ml - treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids). treatment of acyclovir resistant herpes simplex virus (hsv) infections in immunocompromised patients. the safety and efficacy of foscavir for the treatment of other hsv infections (e.g. retinitis, encephalitis); congenital or neonatal disease; or hsv in immunocompetent individuals has not been established.

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - phenelzine sulfate 25.83mg equivalent to phenelzine 15 mg - film coated tablet - 15 mg - active: phenelzine sulfate 25.83mg equivalent to phenelzine 15 mg excipient: magnesium stearate maize starch mannitol opadry red 20a25096 povidone - for the treatment of major depression. phenelzine sulfate should rarely be the first antidepressant medicine used. rather it is more suitable for use with patients who have failed to respond to the medicines more commonly used for these conditions